Patent US4676980A successfully refreshed from Google Patents.
US4676980A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Target specific cross-linked heteroantibodies
Assignee: United States Department of Health and Human Services
•
Filing: 1985-09-23
•
Granted: 1987-06-30
•
Expires: 2005-09-23
Abstract
Abstract The present invention discloses a target specific cross-linked heteroantibody and a method of producing the same. The cross-linked heteroantibodies of the present invention can cause normal autologous cells of the immune system to destroy any unwanted cell for which an antibody is available. Treatment or control of tumors, viral infected cells, fungi, bacteria, parasites and the like is now made possible through the use of the heteroantibody complex of the present invention.
Inventors
- 👤 David M. Segal
- 👤 Pilar Perez
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 18:25
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/46; C07K16/468; C07K2317/00; C07K2317/70; C07K2317/73; C07K2317/732; Y; Y10; Y10S; Y10S436/00; Y10S436/819
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
45 words
Cross-linked antibody heteroaggregates wherein one antibody of the heteroaggregate binds specifically with a receptor entity on a cytotoxic cell and a second antibody of the heteroaggregate binds specifically with a surface entity on a cell different from and to be lysed by the cytotoxic cell.
Claim 2
Dependent Claim
45 words
Cross-linked antibody heteroaggregates wherein one antibody of the heteroaggregate binds specifically with a receptor entity on a cytotoxic cell and a second antibody of the heteroaggregate binds specifically with a surface entity on a cell different from and to be lysed by the cytotoxic cell.
Claim 3
Dependent Claim
24 words
The antibody heteroaggregate of claim 1 wherein said cytotoxic cell is selected from the group consisting of antibody-dependent cytolytic cell and cytotoxic T lymphocytes.
Claim 4
Dependent Claim
24 words
The antibody heteroaggregate of claim 2, wherein the antibodies are cross-linked by avidin coupled to one antibody and biotin coupled to the second antibody.
Claim 5
Independent Claim
20 words
A method of destroying target cells in a mammalian host comprising administering to said host cytolytic amount of cross-linked heteroantibodies.
Claim 6
Independent Claim
20 words
A method of destroying target cells in a mammalian host comprising administering to said host cytolytic amount of cross-linked heteroantibodies.
Claim 7
Independent Claim
34 words
A method of producing target specific heteroantibodies comprising cross-linking a first antibody directed against a receptor entity on a cytotoxic cell with a second antibody directed against a surface component of a target cell.
Claim 8
Independent Claim
34 words
A method of producing target specific heteroantibodies comprising cross-linking a first antibody directed against a receptor entity on a cytotoxic cell with a second antibody directed against a surface component of a target cell.
Claim 9
Dependent Claim
26 words
The method according to claim 5 of cross-linking the first antibody to the second by coupling one antibody with avidin and the second antibody with biotin.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-06-29 | 1990-12-29 | 1991-06-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-06-29 | 1994-12-29 | 1995-06-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-06-29 | 1998-12-29 | 1999-06-30 | $7700.00 | Window Closed / Lapsed |